Bay­er buys Eu­ro­pean rights to Bridge­Bio's AT­TR-CM pill

As Bay­er un­der­goes a ma­jor strat­e­gy re­think, with a full-year 2023 up­date slat­ed for Tues­day, the con­glom­er­ate is en­list­ing ex­ter­nal help to boost its car­dio …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER